Key result
Thrombopoietin receptor agonists are being evaluated in a Cochrane Review protocol for the prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.
Why the study?
Do thrombopoietin receptor agonists (TPO-RAs) prevent or treat chemotherapy-induced thrombocytopenia in patients with solid tumours?
Do thrombopoietin receptor agonists (TPO-RAs) prevent or treat chemotherapy-induced thrombocytopenia in patients with solid tumours?
This is a protocol for a Cochrane Review to evaluate the efficacy of TPO-RAs for chemotherapy-induced thrombocytopenia in solid tumors.
No practice change indicated; protocol leaves open the role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effect of thrombopoietin receptor agonists (TPO‐RAs) to prevent (Part 1) and treat (Part 2) chemotherapy‐induced thrombocytopenia (CIT) in patients with solid tumours.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2016) studied this question. Thrombopoietin receptor agonists are being evaluated in a Cochrane Review protocol for the prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: